Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | IDH1 | O75874 | 1/20 | 0.69 |
| ▸ | CNR1 | P21554 | 3/20 | 0.65 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15871704 | 0.87 | RAB9A (0.76) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL28810823 | 0.86 | KMT2A (0.76) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4106965 | 0.86 | TRPV1 (0.77) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL1815384 | 0.85 | RAB9A (0.80) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4926196 | 0.85 | RAB9A (0.74) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4721638 | 0.85 | RAB9A (0.74) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL5928751 | 0.85 | RAB9A (0.74) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL13695925 | 0.85 | RAB9A (0.80) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4113542 | 0.84 | MAPT (0.72) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4111415 | 0.84 | RAB9A (0.72) | MAPTRAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | MAPT 1654/4885RAB9A 815/4885NPC1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.